Key result
Vitamin E supplementation in patients with MASLD selectively modulates lipid metabolism, predominantly reducing triglyceride levels.
Why the study?
Does Vitamin E improve lipid profiles in patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)?
Meta-Analysis
Does Vitamin E improve lipid profiles in patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)?
Answers are grounded in this paper and cite their sources.
Vitamin E may serve as a potential adjunctive therapy for MASLD-associated dyslipidemia by predominantly reducing triglyceride levels.
, 95% CI: [-0.86, 1.58], p = 0.563). Subgroup analyses revealed that TG was significantly reduced in low-dose, more prolonged supplementation and in overweight patients. For TC, LDL-C, and HDL-C, only a slight, significant improvement was observed in patients with obesity. Vitamin E in patients with MASLD selectively modulates lipid metabolism, predominantly reducing TG levels. Modest improvements in TC, LDL-C, and HDL-C were observed primarily in patients with obesity. These findings support the potential role of vitamin E as an adjunctive therapy for MASLD-associated dyslipidemia.
No takes yet. Share an insight, caveat, or question.
Karimi et al. (2026) conducted a meta-analysis in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Vitamin E was evaluated on Lipid Profile (95% CI -0.86, 1.58, p=0.563). Vitamin E supplementation in patients with MASLD selectively modulates lipid metabolism, predominantly reducing triglyceride levels.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: